Congenital muscular dystrophies: What is new?
Alpha-dystroglycan
COL6-RD
Congenital muscular dystrophy
LAMA2-RD
Lamin a/c
Natural history
Review
SEPN1
Treatments
Journal
Neuromuscular disorders : NMD
ISSN: 1873-2364
Titre abrégé: Neuromuscul Disord
Pays: England
ID NLM: 9111470
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
29
06
2021
revised:
06
07
2021
accepted:
13
07
2021
pubmed:
3
9
2021
medline:
3
2
2022
entrez:
2
9
2021
Statut:
ppublish
Résumé
Congenital muscular dystrophies (CMDs) are a group of inherited conditions defined by muscle weakness occurring before the acquisition of ambulation, delayed motor milestones, and characterised by muscle dystrophic pathology. A large number of genes - at least 35- are responsible for CMD phenotypes, and it is therefore not surprising that CMDs comprise a wide spectrum of phenotypes, with variable involvement of cardiac/respiratory muscles, central nervous system, and ocular structures. The identification of several new genes over the past few years has further expanded both the clinical and the molecular spectrum underlying CMDs. Comprehensive gene panels allow to arrive at a final diagnosis in around 60% of cases, suggesting that both new genes, and unusual mutations of the currently known genes are likely to account for the remaining cases. The aim of this review is to present the most recent advances in this field. We will outline recent natural history studies that provide additional information on disease progression, discuss recently discovered genes and the current status of the most promising therapeutic options.
Identifiants
pubmed: 34470717
pii: S0960-8966(21)00191-7
doi: 10.1016/j.nmd.2021.07.009
pii:
doi:
Substances chimiques
Laminin
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
931-942Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.